Brokerages expect Oxford Immunotec Global (NASDAQ:OXFD) to post sales of $20.98 million for the current quarter, according to Zacks. Four analysts have issued estimates for Oxford Immunotec Global’s earnings. The lowest sales estimate is $20.50 million and the highest is $21.18 million. Oxford Immunotec Global posted sales of $21.51 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 2.5%. The company is scheduled to issue its next earnings report before the market opens on Tuesday, May 1st.

According to Zacks, analysts expect that Oxford Immunotec Global will report full-year sales of $112.30 million for the current financial year, with estimates ranging from $112.00 million to $112.53 million. For the next fiscal year, analysts expect that the firm will post sales of $127.27 million per share, with estimates ranging from $125.54 million to $129.26 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Oxford Immunotec Global.

Oxford Immunotec Global (NASDAQ:OXFD) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.02. The company had revenue of $25.03 million during the quarter, compared to the consensus estimate of $25.12 million. Oxford Immunotec Global had a negative net margin of 31.90% and a negative return on equity of 42.38%. The company’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.22) EPS.

OXFD has been the subject of several research analyst reports. ValuEngine downgraded shares of Oxford Immunotec Global from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Zacks Investment Research upgraded shares of Oxford Immunotec Global from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research note on Friday, March 9th. BidaskClub cut shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research note on Saturday, March 3rd. Finally, Cowen reiterated a “buy” rating and issued a $15.00 price objective on shares of Oxford Immunotec Global in a research note on Monday, January 22nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $17.80.

In other Oxford Immunotec Global news, Director Richard A. Sandberg sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $12.01, for a total transaction of $36,030.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 8.11% of the stock is owned by corporate insiders.

Large investors have recently bought and sold shares of the company. Jefferies Group LLC bought a new stake in shares of Oxford Immunotec Global in the 4th quarter valued at $273,000. Elkfork Partners LLC bought a new stake in shares of Oxford Immunotec Global in the 4th quarter valued at $358,000. Wells Fargo & Company MN boosted its stake in shares of Oxford Immunotec Global by 31.3% in the 3rd quarter. Wells Fargo & Company MN now owns 38,720 shares of the company’s stock valued at $651,000 after purchasing an additional 9,235 shares during the last quarter. Stanley Laman Group Ltd. bought a new stake in shares of Oxford Immunotec Global in the 4th quarter valued at $692,000. Finally, Deutsche Bank AG boosted its stake in shares of Oxford Immunotec Global by 92.8% in the 4th quarter. Deutsche Bank AG now owns 56,878 shares of the company’s stock valued at $793,000 after purchasing an additional 27,384 shares during the last quarter. 93.31% of the stock is currently owned by institutional investors.

Shares of OXFD stock traded down $0.22 during midday trading on Wednesday, hitting $12.31. 60,677 shares of the company were exchanged, compared to its average volume of 199,105. The company has a market capitalization of $324.18, a price-to-earnings ratio of -9.23 and a beta of -0.33. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.92 and a current ratio of 5.37. Oxford Immunotec Global has a 52 week low of $10.00 and a 52 week high of $19.51.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2018/04/23/zacks-analysts-expect-oxford-immunotec-global-oxfd-will-announce-quarterly-sales-of-20-98-million.html.

About Oxford Immunotec Global

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.

Get a free copy of the Zacks research report on Oxford Immunotec Global (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Oxford Immunotec Global (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.